Overcoming structural barriers to diffusion of HIV pre-exposure prophylaxis


HIV prevention with antiretroviral medication in the form of pre-exposure prophylaxis (PrEP) offers a critical tool to halt the HIV pandemic. Barriers to PrEP access across drug types, formulations, and delivery systems share remarkable commonalities and are likely to be generalizable to future novel PrEP strategies. Appreciation of these barriers allows for planning earlier in the drug-development pathway rather than waiting for the demonstration of efficacy. The purpose of this article is to propose a core set of considerations that should be included in the drug-development process for future PrEP interventions. A literature synthesis of key barriers to PrEP uptake in the United States was conducted to elucidate commonalities across PrEP agents and delivery methods. Based on the published literature, we divided challenges into three main categories of structural barriers: (1) provider and clinic characteristics; (2) cost considerations; and (3) disparities and social constructs, with potential solutions provided for each. Pragmatic strategies for examining and overcoming these barriers before future PrEP regulatory approval are recommended. If these strategies are considered well before the time of commercial availability, the potential for PrEP to interrupt the HIV pandemic will be greatly enhanced.


Magnus M, Yellin H, Langlands K, Balachandran M, Turner M, Jordan J, Ramin D, Kuo I, Siegel M




  • Epidemiology and Determinants of Health
    • Determinants of Health
  • Determinants of Health
    • Health services
  • Population(s)
    • General HIV- population
  • Prevention, Engagement and Care Cascade
    • Prevention
  • Prevention
    • Biomedical interventions
  • Health Systems
    • Financial arrangements


Abstract/Full paper

Email 1 selected articles

Email 1 selected articles

Error! The email wasn't sent. Please try again.

Your email has been sent!